|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Markowitz SD and Bertagnolli MM: Molecular
origins of cancer: Molecular basis of colorectal cancer. N Engl J
Med. 361:2449–2460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Andersen V, Vogel LK, Kopp TI, Sæbø M,
Nonboe AW, Hamfjord J, Kure EH and Vogel U: High ABCC2 and low
ABCG2 gene expression are early events in the colorectal
adenoma-carcinoma sequence. PLoS One. 10:e01192552015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Saika K and Sobue T: Cancer statistics in
the world. Gan To Kagaku Ryoho. 40:2475–2480. 2013.(In Japanese).
PubMed/NCBI
|
|
5
|
Mastalier B, Tihon C, Ghiţă B, Botezatu C,
Deaconescu V, Mandisodza P, Drăghici C and Simion S: Surgical
treatment of colon cancer: Colentina surgical clinic experience. J
Med Life. 5:348–353. 2012.PubMed/NCBI
|
|
6
|
Van Cutsem E, Nordlinger B and Cervantes
A: ESMO Guidelines Working Group: Advanced colorectal cancer: ESMO
Clinical Practice Guidelines for treatment. Ann Oncol. 21 Suppl
5:v93–v97. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu J, Mo Y, Wang X, Liu J, Zhang X, Wang
J, Hu L, Yang C, Chen L and Wang Y: Conditionally replicative
adenovirus-based mda-7/IL-24 expression enhances sensitivity of
colon cancer cells to 5-fluorouracil and doxorubicin. J
Gastroenterol. 48:203–213. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shain KH and Dalton WS: Cell adhesion is a
key determinant in de novo multidrug resistance (MDR): New targets
for the prevention of acquired MDR. Mol Cancer Ther. 1:69–78.
2001.PubMed/NCBI
|
|
9
|
Bellacosa A, Kumar CC, Di Cristofano A and
Testa JR: Activation of AKT kinases in cancer: Implications for
therapeutic targeting. Adv Cancer Res. 94:29–86. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Katso R, Okkenhaug K, Ahmadi K, White S,
Timms J and Waterfield MD: Cellular function of phosphoinositide
3-kinases: Implications for development, homeostasis, and cancer.
Annu Rev Cell Dev Biol. 17:615–675. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tazzari PL, Cappellini A, Ricci F,
Evangelisti C, Papa V, Grafone T, Martinelli G, Conte R, Cocco L,
McCubrey JA, et al: Multidrug resistance-associated protein 1
expression is under the control of the phosphoinositide 3
kinase/Akt signal transduction network in human acute myelogenous
leukemia blasts. Leukemia. 21:427–438. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shekari F, Sadeghpour H, Javidnia K, Saso
L, Nazari F, Firuzi O and Miri R: Cytotoxic and multidrug
resistance reversal activities of novel 1,4-dihydropyridines
against human cancer cells. Eur J Pharmacol. 746:233–244. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stepanenko AA, Andreieva SV, Korets KV,
Mykytenko DO, Baklaushev VP, Huleyuk NL, Kovalova OA, Kotsarenko
KV, Chekhonin VP, Vassetzky YS, et al: Temozolomide promotes
genomic and phenotypic changes in glioblastoma cells. Cancer Cell
Int. 16:362016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pharmacopoeia of the People's Republic of
China. China Medical Science Press; Beijing: pp. 109–110. 2010
|
|
15
|
Wei L, Lin J, Wu G, Xu W, Li H, Hong Z and
Peng J: Scutellaria barbata D. Don induces G1/S arrest via
modulation of p53 and Akt pathways in human colon carcinoma cells.
Oncol Rep. 29:1623–1628. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wei L, Lin J, Xu W, Cai Q, Shen A, Hong Z
and Peng J: Scutellaria barbata D. Don inhibits tumor
angiogenesis via suppression of Hedgehog pathway in a mouse model
of colorectal cancer. Int J Mol Sci. 13:9419–9430. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wei L, Lin J, Xu W, Hong Z, Liu X and Peng
J: Inhibition of tumor angiogenesis by Scutellaria barbata
D. Don via suppressing proliferation, migration and tube formation
of endothelial cells and downregulation of the expression of VEGF-A
in cancer cells. J Med Plants Res. 5:3260–3268. 2011.
|
|
18
|
Lin L, Liu Y, Li H, Li PK, Fuchs J,
Shibata H, Iwabuchi Y and Lin J: Targeting colon cancer stem cells
using a new curcumin analogue, GO-Y030. Br J Cancer. 105:212–220.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lippman SM: The dilemma and promise of
cancer chemoprevention. Nat Clin Pract Oncol. 3:5232006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Longley DB, Allen WL and Johnston PG: Drug
resistance, predictive markers and pharmacogenomics in colorectal
cancer. Biochim Biophys Acta. 1766:184–196. 2006.PubMed/NCBI
|
|
21
|
Van Cutsem E and Costa F: Progress in the
adjuvant treatment of colon cancer: Has it influenced clinical
practice? JAMA. 294:2758–2760. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ji T, Lin C, Krill LS, Eskander R, Guo Y,
Zi X and Hoang BH: Flavokawain B, a kava chalcone, inhibits growth
of human osteosarcoma cells through G2/M cell cycle arrest and
apoptosis. Mol Cancer. 12:552013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu G, Chu J, Huang Z, Ye J, Chen P, Zheng
C, Li X, Liu X and Wu M: Xiao Jin Wan, a traditional Chinese herbal
formula, inhibits proliferation via arresting cell cycle
progression at the G2/M phase and promoting apoptosis via
activating the mitochondrial-dependent pathway in U-2OS human
osteosarcoma cells. Int J Oncol. 42:1070–1080. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zheng SE, Xiong S, Lin F, Qiao GL, Feng T,
Shen Z, Min DL, Zhang CL and Yao Y: Pirarubicin inhibits
multidrug-resistant osteosarcoma cell proliferation through
induction of G2/M phase cell cycle arrest. Acta Pharmacol Sin.
33:832–838. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wesarg E, Hoffarth S, Wiewrodt R, Kröll M,
Biesterfeld S, Huber C and Schuler M: Targeting BCL-2 family
proteins to overcome drug resistance in non-small cell lung cancer.
Int J Cancer. 121:2387–2394. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao Y, Zhang CL, Zeng BF, Wu XS, Gao TT
and Oda Y: Enhanced chemosensitivity of drug-resistant osteosarcoma
cells by lentivirus-mediated Bcl-2 silencing. Biochem Biophys Res
Commun. 390:642–647. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Deeley RG, Westlake C and Cole SP:
Transmembrane transport of endo- and xenobiotics by mammalian
ATP-binding cassette multidrug resistance proteins. Physiol Rev.
86:849–899. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qiao D, Tang S, Aslam S, Ahmad M, To KK,
Wang F, Huang Z, Cai J and Fu L: UMMS-4 enhanced sensitivity of
chemotherapeutic agents to ABCB1-overexpressing cells via
inhibiting function of ABCB1 transporter. Am J Cancer Res.
4:148–160. 2014.PubMed/NCBI
|
|
30
|
Chen Z, Liu F, Ren Q, Zhao Q, Ren H, Lu S,
Zhang L and Han Z: Suppression of ABCG2 inhibits cancer cell
proliferation. Int J Cancer. 126:841–851. 2010.PubMed/NCBI
|
|
31
|
Zhang H, Wang YJ, Zhang YK, Wang DS,
Kathawala RJ, Patel A, Talele TT, Chen ZS and Fu LW: AST1306, a
potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G
member 2-mediated multidrug resistance. Cancer Lett. 350:61–68.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ee PL, He X, Ross DD and Beck WT:
Modulation of breast cancer resistance protein (BCRP/ABCG2) gene
expression using RNA interference. Mol Cancer Ther. 3:1577–1583.
2004.PubMed/NCBI
|
|
33
|
Giampieri R, Scartozzi M, Loretelli C,
Piva F, Mandolesi A, Lezoche G, Del Prete M, Bittoni A, Faloppi L,
Bianconi M, et al: Cancer stem cell gene profile as predictor of
relapse in high risk stage II and stage III, radically resected
colon cancer patients. PLoS One. 8:e728432013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang X and Morris ME: Effects of the
flavonoid chrysin on nitrofurantoin pharmacokinetics in rats:
Potential involvement of ABCG2. Drug Metab Dispos. 35:268–274.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu KJ, He JH, Su XD, Sim HM, Xie JD, Chen
XG, Wang F, Liang YJ, Singh S, Sodani K, et al: Saracatinib
(AZD0530) is a potent modulator of ABCB1-mediated multidrug
resistance in vitro and in vivo. Int J Cancer. 132:224–235. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang HW, Hua MY, Liu HL, Tsai RY, Pang ST,
Hsu PH, Tang HJ, Yen TC and Chuang CK: An epirubicin-conjugated
nanocarrier with MRI function to overcome lethal
multidrug-resistant bladder cancer. Biomaterials. 33:3919–3930.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sane R, Mittapalli RK and Elmquist WF:
Development and evaluation of a novel microemulsion formulation of
elacridar to improve its bioavailability. J Pharm Sci.
102:1343–1354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Arafa SA, Zhu Q, Shah ZI, Wani G, Barakat
BM, Racoma I, El-Mahdy MA and Wani AA: Thymoquinone up-regulates
PTEN expression and induces apoptosis in doxorubicin-resistant
human breast cancer cells. Mutat Res. 706:28–35. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hegedüs C, Truta-Feles K, Antalffy G,
Brózik A, Kasza I, Német K, Orbán TI, Özvegy-Laczka C, Váradi A and
Sarkadi B: PI3-kinase and mTOR inhibitors differently modulate the
function of the ABCG2 multidrug transporter. Biochem Biophys Res
Commun. 420:869–874. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang Y, Wang J, Ren M, Li M, Chen D, Chen
J, Shi F, Wang X and Dou J: Gene therapy of ovarian cancer using
IL-21-secreting human umbilical cord mesenchymal stem cells in nude
mice. J Ovarian Res. 7:82014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kono T, Hata T, Morita S, Munemoto Y,
Matsui T, Kojima H, Takemoto H, Fukunaga M, Nagata N, Shimada M, et
al: Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): A
phase 2, multicenter, randomized, double-blind, placebo-controlled
trial of goshajinkigan to prevent oxaliplatin-induced neuropathy.
Cancer Chemother Pharmacol. 72:1283–1290. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pallis M and Russell N: P-glycoprotein
plays a drug-efflux-independent role in augmenting cell survival in
acute myeloblastic leukemia and is associated with modulation of a
sphingomyelin-ceramide apoptotic pathway. Blood. 95:2897–2904.
2000.PubMed/NCBI
|
